Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation

BACKGROUND: Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate LVAD thrombosis. Phosphodiesterase type 5 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xanthopoulos, Andrew, Tryposkiadis, Konstantinos, Triposkiadis, Filippos, Fukamachi, Kiyotaka, Soltesz, Edward G., Young, James B., Wolski, Kathy, Blackstone, Eugene H., Starling, Randall C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660717/
https://www.ncbi.nlm.nih.gov/pubmed/32648508
http://dx.doi.org/10.1161/JAHA.119.015897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660717/
https://www.ncbi.nlm.nih.gov/pubmed/32648508
http://dx.doi.org/10.1161/JAHA.119.015897

Ejemplares similares